The biopharmaceutical company Harmony Biosciences, which focuses on neuroscience, has announced that its management team will participate in two upcoming investor conferences. Company executives will present business updates and strategic plans at these events.

Conference Schedule: According to the announcement, Harmony Biosciences will attend the following two conferences: A fireside chat at Goldman Sachs' 47th Annual Global Healthcare Conference is scheduled for 8:40 AM on June 9, 2026, in Miami, Florida. A fireside chat at the Oppenheimer CNS & Neuromuscular Summit is scheduled for 3:25 PM on June 10, 2026, also in Miami, Florida. Live webcasts of both fireside chats will be available on the investor relations section of the Harmony Biosciences website, with replays provided after the events.

First Quarter Performance: Core Product WAKIX Maintains Growth Approximately three weeks prior to this announcement, Harmony Biosciences reported its financial results for the first quarter of 2026. Net product revenue for its core product, WAKIX, reached $215.4 million in the quarter, representing a 17% year-over-year increase and continuing its strong growth trajectory. The product is used to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy.

The company also reaffirmed its full-year 2026 revenue guidance, projecting net product revenue to be between $1.0 billion and $1.04 billion. Since its launch in 2020, WAKIX has achieved a five-year compound annual growth rate of approximately 40%, and management is confident about reaching the $1 billion milestone this year.

Regarding patient data, the average number of patients on WAKIX therapy reached 8,500 in Q1 2026, setting a new record high for the third consecutive quarter, with a net increase of over 400 patients per quarter. The number of patients on therapy at the end of the quarter was 8,600, providing a solid foundation for entering the second quarter.

Earnings Pressure: Strategic Investments Drive Increased R&D Spending Despite strong revenue performance, the company's net income for the first quarter was $32.5 million, with diluted earnings per share of $0.55, down from $0.78 in the same period last year. The decline in profitability is primarily attributed to a significant increase in strategic investments in the company's research and development pipeline.

Research and development expenses increased by 101% year-over-year to $69.4 million, of which approximately $32 million was related to an upfront payment associated with an amorphous pitolisant licensing agreement signed in the first quarter. Excluding this one-time expense, operating expenses grew only moderately, by approximately 5%.

The company's balance sheet remains healthy. As of March 31, 2026, cash, cash equivalents, and investments totaled $870.5 million, providing ample financial resources for advancing the pipeline and potential business development.

Pipeline Progress: Multiple Late-Stage Projects Show Promise Harmony Biosciences is advancing several late-stage clinical programs. The company submitted a New Drug Application for its pitolisant enteric-coated formulation in the second quarter of 2026, with an FDA review decision expected in the first quarter of 2027. A high-dose pitolisant formulation is in Phase 3 registration trials for narcolepsy and idiopathic hypersomnia.

In the epilepsy field, the Phase 3 ARGUS study of EPX-100 for Dravet syndrome is ongoing, with topline data expected in the first half of 2027. Additionally, the company's orexin-2 receptor agonist, BP1.15205, has dosed its first subject, and Phase 1 pharmacokinetic data is expected to be announced in mid-2026.

Recent Developments Notably, the company appointed Glenn Reicin as its new Chief Financial Officer in April 2026 and previously announced an expansion of its executive team and Board of Directors. The company also held its Annual General Meeting on May 14, where matters including the election of four Class III directors were addressed.

The market will be closely watching for any updates on business progress and pipeline milestone expectations at the upcoming investor conferences. At the time of writing, Harmony Biosciences' stock was trading at approximately $30.50, with a market capitalization of around $1.8 billion.